Research Article

Gene Therapy of Multiple Sclerosis Using Interferon $\beta$-Secreting Human Bone Marrow Mesenchymal Stem Cells

Chung Heon Ryu, Kwang Ywel Park, Yun Hou, Chang Hyun Jeong, Seong Muk Kim, and Sin-Soo Jeun

1 Postech-Catholic Biomedical Engineering Institute, Seoul St. Mary’s Hospital, The Catholic University of Korea, 505 Banpo-daero, Seocho-gu, Seoul 137-701, Republic of Korea
2 Department of Biomedical Science, College of Medicine, The Catholic University of Korea, 505 Banpo-daero, Seocho-gu, Seoul 137-701, Republic of Korea
3 Department of Neurosurgery, Seoul St. Mary’s Hospital, The Catholic University of Korea, 505 Banpo-daero, Seocho-gu, Seoul 137-701, Republic of Korea

Correspondence should be addressed to Sin-Soo Jeun; ssjeun@catholic.ac.kr

Received 6 February 2013; Accepted 3 April 2013

Academic Editor: Kok Tat Tan

Copyright © 2013 Chung Heon Ryu et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Interferon-beta (IFN-$\beta$), a well-established standard treatment for multiple sclerosis (MS), has proved to exhibit clinical efficacy. In this study, we first evaluated the therapeutic effects for MS using human bone marrow-derived mesenchymal stem cells (hBM-MSCs) as delivery vehicles with lesion-targeting capability and IFN-$\beta$ as therapeutic gene. We also engineered hBM-MSCs to secret IFN-$\beta$ (MSCs-IFN$\beta$) via adenoviral transduction and confirmed the secretory capacity of MSCs-IFN$\beta$ by an ELISA assay. MSCs-IFN$\beta$-treated mice showed inhibition of experimental autoimmune encephalomyelitis (EAE) onset, and the maximum and average score for all animals in each group was significantly lower in the MSCs-IFN$\beta$-treated EAE mice when compared with the MSCs-GFP-treated EAE mice. Inflammatory infiltration and demyelination in the lumbar spinal cord also significantly decreased in the MSCs-IFN$\beta$-treated EAE mice compared to PBS- or MSCs-GFP-treated EAE mice. Moreover, MSCs-IFN$\beta$ treatment enhanced the immunomodulatory effects, which suppressed proinflammatory cytokines (IFN-$\gamma$ and TNF-$\alpha$) and conversely increased anti-inflammatory cytokines (IL-4 and IL-10). Importantly, injected MSCs-IFN$\beta$ migrated into inflamed CNS and significantly reduced further injury of blood-brain barrier (BBB) permeability in EAE mice. Thus, our results provide the rationale for designing novel experimental protocols to enhance the therapeutic effects for MS using hBM-MSCs as an effective gene vehicle to deliver the therapeutic cytokines.

1. Introduction

Multiple sclerosis (MS) is an autoimmune-mediated inflammatory disease in which the myelin sheaths around the axons of the central nervous system (CNS) are damaged, leading to demyelination and neuronal loss [1]. MS is characterized by multiple signs and symptoms, with remissions and recurring exacerbations of the disease. A number of experimental treatments have been developed to improve the survival for patients with MS. There are several approved therapies for MS, such as glatiramer acetate and mitoxantrone, which mainly target the immunological aspects [2, 3]. Although there are several approved drugs for MS, many patients do not respond optimally to these drugs. Therefore, developing more effective therapeutic protocols for MS is necessary. Experimental allergic encephalomyelitis (EAE) is an animal model of CNS autoimmune disease that follows immunization with certain CNS antigens. The EAE model has been widely used as a human MS model, and many clinical and histopathological similarities to human MS have been reported [4].

Mesenchymal stem cells (MSCs) are adult multipotent cells that differentiate into the mesenchymal lineages of adipocytes, osteocytes, and chondrocytes. Currently, MSCs
are investigated in preclinical and clinical settings because of their self-renewal capacity, ability to differentiate into multiple lineages, and immunosuppressive activity [5, 6]. Moreover, MSCs can migrate to areas of injury [7]. This pathotropism of MSCs makes them useful for the regeneration of damaged tissues as well as for targeted delivery of therapeutic genes to sites of pathology. Recently, allogenic human bone marrow stromal cells treatment also improved functional recovery after EAE in mice, possibly, via reducing inflammatory infiltrates and demyelination areas, stimulating oligodendrogenesis, and by elevating BDNF expression [10]. These data indicated that hBM-MSCs could be used as the promising delivery vehicle of therapeutic gene against EAE.

Interferon-beta (IFN-\(\beta\)) as one of the promising treatments for MS is approved for the treatment of relapsing-remitting MS. IFN-\(\beta\) treatments have been shown to produce about 18%-38% reduction in the rate of MS relapses and to slow the progression of disability in MS patients [11]. Its exact mechanism of action for MS therapy is unknown but probably includes the regulation of T-cell activation and immune cell proliferation, autoreactive T-cell apoptosis, IFN-\(\gamma\) antagonism, modulation of proinflammatory (Th1)/anti-inflammatory (Th2) cytokines, and inhibition of immune cell trafficking across the blood-brain barrier (BBB) [12]. Despite the impressive therapeutic effects in the experimental studies for MS, clinical trials using IFN-\(\beta\) treatment have poor outcome [11]. One of the main problems is the insufficient duration of recombinant IFN-\(\beta\), short half-life in vivo, and its inaccessibility to the CNS. A second problem is the presence of BBB, preventing many therapeutics, especially large and/or charged molecules, from reaching the brain and spinal cord to treat disorders of the CNS [13]. To overcome these problems, we used hBM-MSCs as IFN-\(\beta\) gene delivery vehicles with CNS targeting migration capabilities and evaluated the therapeutic efficiency of IFN-\(\beta\)-secreting hBM-MSCs (MSCs-IFN\(\beta\)) in EAE.

2. Materials and Methods

2.1. Mesenchymal Stem Cell Culture and Adenovirus Infection. MSCs derived from the human bone marrow were purchased from Lonza (Walkersville, Maryland, USA). The MSCs were subcultured at a concentration of \(5 \times 10^6\) cells/cm\(^2\) in MSC growth medium (Lonza) and used for experiments during passages 5 to 8. The recombinant adenoviral vector encoding the gene for EGFP (Ad-GFP) and mouse IFN-\(\beta\) (Ad-IFN-\(\beta\)) was constructed and produced using the AdEasy vector system, following the manufacturer's instructions (Quantum Biotechnologies, Carlsbad, CA, USA). MSCs were infected with 50 multiplicity of infection of Ad-GFP or Ad-IFN-\(\beta\), as described previously [14].

2.2. EAE Induction and Treatments. EAE was induced in female C57BL/6 mice (10 weeks old, Charles River Laboratories) using immunization with MOG35–55. The mice were injected subcutaneously at two sites with a total of 200 \(\mu\)g of MOG35–55 emulsified in complete Freund's adjuvant (CFA) containing 6 mg/mL of Mycobacterium tuberculosis. Two h and twenty four h after the MOG35–55 injection, the mice received 100 ng Bordetella pertussis toxin intraperitoneally, respectively. Mice were scored as follows: 0: no clinical signs; 1: limp tail; 2: partial hind leg paralysis; 3: complete hind leg paralysis; 4: complete hind leg paralysis and partial front leg paralysis; and 5: moribund or dead. Mice were randomly divided into three groups and were injected intravenously (IV) on day 7 after immunization: PBS (\(n = 7\)), MSCs-GFP (\(n = 7, 1 \times 10^6\) cells/each mouse), and MSCs-IFN\(\beta\) (\(n = 7, 1 \times 10^6\) cells/each mouse).

2.3. Histological Analysis of Demyelination and Inflammatory Infiltration. Histological evaluation was performed on 4% paraformaldehyde fixed, O.C.T-embedded sections of lumbar spinal cords of EAE mice at day 37 after immunization. Frozen sections were stained with luxol fast blue (LFB) and hematoxylin-eosin (H&E) for evaluating inflammatory infiltration and demyelination, respectively. Quantification was performed on 3 sections per animal and 4 animals per group. The infiltration cells were counted by investigators blinded to the status of the animal. The average of infiltrated cell number and the intensity of demyelinated axons was determined from randomly selected areas within the lesion areas from at least 3 sections taken from the same spinal cord level from 4 animals in each group. All images were measured via a computer using the MetaMorph software (Molecular Devices, Downingtown, PA, USA).

2.4. Determination of Cytokines by ELISA and ELISPOT. Serum was obtained from three animals for each treatment group at day 37 after immunization. ELISA was performed to measure the concentrations of IFN-\(\gamma\), TNF-\(\alpha\), IL-4, and IL-10 using Quantikine immunoassay kits from R&D systems (Minneapolis, MN). Enzyme-linked immunospot (ELISPOT) kit for the detection the IFN-\(\gamma\) and IL-4 was purchased from R&D systems. Briefly, the plates were blocked for 1h with sterile PBS, containing 1% BSA, and washed 3 times with sterile PBS. Splenocytes (5 \(\times\) 10\(^5\)/well) isolated from each treatment group and incubated with MOG35–55 (10 \(\mu\)g/mL) at 37°C for 48 h and then washed. Biotinylated antibody, streptavidin-AP, and NBT/5-bromo-4-chloro-3-indolyl phosphate substrate (Vector Labs, Burlingame) were used to detect IFN-\(\gamma\) and IL-4 secretion. Spots were counted using the Zeiss Microscopy (Oberkochen, Germany).

2.5. Reverse Transcription Polymerase Chain Reaction (RT-PCR). Total RNA was prepared from the cerebral cortex using TRizol (Invitrogen, Grand Island, NY), according to the manufacturer’s instructions. cDNA was synthesized using \(2 \mu\)g total RNA and oligo(dT) primer and Superscript II polymerase for reverse transcription PCR (Invitrogen). PCR amplifications consisted of a total of 32 cycles of
Figure 1: In vitro and in vivo transgene expression for MSCs-IFNβ. (a) IFN-β protein production was detected in supernatants from IFN-β-transduced MSCs by ELISA. MSCs-GFP was used as a control. (b) For the quantification of secreted IFN-β and longevity of IFN-β expression in EAE, serum was isolated on different days (n = 3/each group) after treatment and then assessed by ELISA. Columns: mean; bars: SE. The results are representative of three independent experiments.

Figure 2: Clinical severity of EAE mice treated with MSCs-IFNβ. (a) EAE was induced in female C57 BL/6 mice by the immunization with the MOG35–55. After day 7, immunized mice were either treated with PBS, MSCs-GFP, or MSCs-IFNβ, and the MSCs-IFNβ group (n = 7/each group) resulted in a significant amelioration of clinical symptoms. (b) The maximum and average scores for all animals in the PBS-, MSCs-GFP- and MSCs-IFNβ-treated EAE mice over the 60-day period (n = 7/each group). Columns: mean; bars: SE. *P < 0.05, **P < 0.01, and Student’s t-test. The results are representative of three independent experiments.

denaturation at 94°C for 30 sec, annealing at 54°C for 30 sec, extension at 72°C for 1 min with a first denaturation at 94°C for 7 min, and final extension at 72°C for 7 min. Target primers sequences used were as follows: BDNF forward: 5'-TGTGACAGTATTAGCGAGTGGGT-3'; BDNF reverse: 5'-ACGATTGGGTAGTTCGGCATT-3'; NGF forward: 5'-ACTCTGTCCCTGAAGCCCACTG-3'; NGF reverse: 5'-TGTTGCGGGTCTGCCCTGTC-3'; and GAPDH forward: 5'-TCCATGACAACTTTGGTATCG-3'; GAPDH reverse: 5'-TGTAGCCAAATTCGTTGTCA-3'.

2.6. In Vivo Fluorescence Imaging Analysis. IV-injected near infrared (NIR)-labeled MSCs-IFNβ were tracked along time
using the CRi Maestro in vivo imaging system (CRI, Inc., Woburn, MA), which allows the detection of labeled cells in each animal tissue. In brief, mice were anesthetized by gas mixtures of 1.5% isoflurane and air and then imaged. The biofluorescence signals (photons/sec) emitted from the mice were captured by a high-sensitivity charge-coupled device camera and analyzed using the Maestro software. Spectral unmixing algorithms were applied to create unmixed images of fluorescein and autofluorescence. To validate the sensitivity and specificity of this method, NIR-labeled MSCs-IFNβ in the brain and spinal cord were detected by immunofluorescence staining using an anti-hNA (human nuclear antigen) polyclonal antibody (Molecular Probes, Eugene, OR), followed by detection with an anti-rabbit secondary antibody conjugated with Alexa 488 (Molecular Probes).

2.7. Fluorescent Detection of Evans Blue Dye. The uptake of the Evans blue (EB) tracer marker from circulation into the cerebrum and spinal cord tissues was measured using a spectrophotometer. Briefly, 4% EB was infused by IV injection in the tail vein in each mouse in the control groups as well as individual mice identified from the experimental EAE groups at the peak of clinical disease. After 4 hours, the mice were sacrificed by transcardiac perfusion with PBS, and the spinal cords removed and homogenized in 0.5% TritonX-100. The supernatants were plated 100 μL/well in triplicate in a flat-bottom 96 well plate, and fluorescence was quantified by using a microplate fluorescence reader (PerkinElmer, Wellesley, MA, USA), (excitation: 620 nm; emission: 680 nm). Values are presented as intensity of fluorescence and represent average values for at least three mice per group.

2.8. Statistical Analysis. All data are expressed as the mean ± SEM. Statistical differences between different test conditions were determined using Student’s t-test. Probability values less than 0.05 were considered significant.
**3. Results and Discussion**

3.1. Clinical Status of IFN-β Secreting MSCs Transplanted Mice after EAE Induction. In this study, we first used hBM-MSCs as vehicles to deliver IFN-β gene for MS therapy. hBM-MSCs have a number of advantages over other stem cell types. It can be easily obtained from human bone marrow upon bone biopsy, expand in vitro, and can inhibit the proliferation of T, B, and dendritic cells through the induction of cell division arrest. hBM-MSCs can also inhibit the proliferation of natural killer cells and impair antigen presentation. Moreover, allogenic human MSCs have been recently proposed for the treatment of acute graft-versus-host disease (GVHD) [8]. Thus, immunomodulatory capacities of hBM-MSCs may also provide a synergistic therapeutic effect for EAE. MS is a chronic inflammatory disorder which usually requires long-term treatment. Recombinant IFN-β (rIFN-β) is currently the most common therapy for MS. At present, two IFN-β drugs (IFN-β1b and IFN-β1a) have been approved for treatment of MS: IFN-β1b 250 mg subcutaneous (s.c.) every other day, IFN-β1a 22 mg s.c. three times per week, and IFN-β1a 30 mg intramuscular (i.m.) once a week [15]. Administration of rIFN-β is typically associated with peak and trough kinetics governed by the biologic half-life of the protein. IFN-β has a very short half-life in the serum. Moreover, long-term repeated injections of rIFN-β are associated with several clinically relevant side effects, including depression, inflammation, and liver toxicity [16]. In this experiment, IFN-β-transduced MSCs (MSCs-IFNβ) could provide a long-term expression of IFN-β at therapeutic concentration. To identify whether MSCs-IFNβ can secrete IFN-β protein in vitro and injected MSCs-IFNβ survived in vivo for a sufficient length of time to allow a therapeutic effect to occur, we measured the levels of IFN-β protein and its longevity in EAE mice serum. IFN-β in supernatants from MSCs-IFNβ was detected from day 3 and persisted to day 40. IFN-β in supernatants from GFP-transduced MSCs (MSCs-GFP) as control could not be detected with this method (Figure 1(a)). ELISA analysis on different days after MSCs-IFNβ treatment in EAE also revealed that the IFN-β protein expressed in serum peaked on day 7, began to decrease after day 13, and persisted for 3 weeks (Figure 1(b)). Additionally, IFN-β protein was detected in the serum of mice transplanted with MSCs-IFNβ at higher levels than those expressed in mice transplanted with MSCs-GFP. The low level of IFN-β protein in the serum of mice transplanted with MSCs-GFP as control could be due to the induction by the MSCs transplantation, as MSCs are known to induce the secretion of beneficial cytokines by...
We observed that within the first 14 days of MSCs-IFNβ by each animal from day 0 to day 40 after immunization. We also measured the mean maximum and average score achieved by each mouse. The number of infiltrated cells in three sections from each of the three animals in each treatment group was counted. A statistically significant decrease in the infiltrated cells into the spinal cord was observed in the MSCs-IFNβ-treated group compared to the PBS- and MSCs-GFP treated EAE mice (Figure 3(a)). These results suggest that MSCs-IFNβ could effectively improve histological outcomes via reduced inflammatory infiltrates and demyelination in EAE.

### 3.2. MSCs-IFNβ Reduced Inflammation and Demyelination of Lumbar Spinal Cords in EAE Mice

The hallmarks of MS include multifocal perivascular mononuclear inflammatory infiltration in the CNS, oligodendrocyte loss, and demyelination [1]. The most important histopathological changes in animals with EAE were detected in the lumbar spinal cord. H&E staining revealed an apparent infiltration of leukocytes into a white matter of the lumbar spinal cord in the PBS- and MSCs-GFP treated EAE mice, but this inflammatory infiltrates were significantly reduced by MSCs-IFNβ. The number of infiltrated cells in three sections from each of the three animals in each treatment group was counted. A statistically significant decrease in the infiltrated cells into the spinal cord was observed in the MSCs-IFNβ-treated group compared to the PBS- and MSCs-GFP treated EAE mice (Figure 3(a)). Next, the presence of demyelination was evaluated by LFB staining. Corresponding with inflammatory infiltrates, MSCs-IFNβ significantly inhibited demyelination in the white matter of the lumbar spinal cord of EAE mice (P < 0.01) (Figure 3(b)). These results suggest that MSCs-IFNβ could effectively improve histological outcomes via reduced inflammatory infiltrates and demyelination in EAE.

### 3.3. MSCs-IFNβ Modulated the Levels of Th1 and Th2 Cytokines in the Serum of EAE Mice

To determine whether the MSCs-IFNβ show immunomodulatory effects on EAE, we evaluated levels of Th1 (IFN-γ, TNF-α) and Th2 (IL-4, IL-10) cytokines in the serum of EAE mice after MSCs-IFNβ treatment during the relapsing phase at day 30 after the EAE induction. Cytokine levels of IFN-γ and TNF-α were significantly reduced in the MSCs-IFNβ treatment group compared to the PBS- or MSCs-GFP treatment groups (P < 0.05). However, levels of IL-4 and IL-10 were significantly increased in the MSCs-IFNβ treatment group compared to the PBS- or MSCs-GFP treatment groups (P < 0.05) (Figure 4(a)). In addition, we confirmed the production of IFN-γ and IL-4 in anti-MOG35–55 stimulated splenocytes after MSCs-IFNβ treatment. The number of MOG-specific IFN-γ/IL-4 producing splenocytes was determined by ELISPOT assay. Stereological analysis revealed a significant decrease in IFN-γ and a significant increase in IL-4 secretion in the MSCs-IFNβ treatment group compared to the PBS- or MSCs-GFP treatment groups (P < 0.01) (Figure 4(b)). These results indicate that MSCs-IFNβ systemically affect the effector phase of the disease. Collectively, it appears that there is a significant shift from the Th1 to the Th2 cytokine balance in the MSCs-IFNβ treatment of EAE mice, compared to PBS- or MSCs-GFP treatment groups.

### 3.4. MSCs-IFNβ Induced Neurotrophins in the Brain of EAE Mice

The beneficial effects produced by MSCs-IFNβ treatment might be attributed not only to immunomodulatory...
activity but also to neuroprotective effects. The neuroprotective aspect of inflammation has been documented and is thought to be mediated by neurotrophins (NTs). NTs, such as brain-derived neurotrophic factor (BDNF) and nerve growth factor (NGF), have a dramatic effect on neuron and oligodendrocyte survival, stimulating axonal regeneration and remyelination, and have been reported to be reduced in EAE [18]. Furthermore, some of the approved therapies for MS such as IFN-β and glatiramer acetate could exert their beneficial effects by affecting these two NTs in EAE mice. To address this possibility in our experiment, we investigated the mRNA expression of BDNF and NGF in the brain of EAE mice after MSCs-IFNβ treatment. The transcription level of BDNF and NGF was dramatically higher in MSCs-IFNβ-treated mice than that in PBS- or MSCs-GFP-treated mice (P < 0.01) (Figure 5). It has been reported that IFN-β was a potent promoter of NGF production by astrocytes and could induce BDNF production of peripheral blood mononuclear cells in MS patients [19]. Furthermore, NGF has immunomodulatory action on the balance between Th1 and Th2 cytokines, while Th1/Th2 immune deviation plays a pivotal role in chronic progressive and relapsing-remitting EAE [20]. Thus, IFN-β secreted from MSCs-IFNβ could effectively modulate the balance of proinflammatory (Th1) and anti-inflammatory (Th2) cytokines by inducing NTs in EAE mice.

3.5. MSCs-IFNβ Migrate Inflamed Brain and Spinal Cord and Regulate BBB Permeability. In previous studies, we demonstrated that MSCs have a strong migratory capacity toward injury site and that genetically modified MSCs also have tropism for injury area and improve neurological functional recovery of neurodegenerative diseases [7, 14]. To test this in MSCs-IFNβ, in vivo migration assays using in vivo image analysis system. In normal animals, IV injection of MSCs-IFNβ results in their accumulation in the lung and liver, whereas in EAE mice, the biofluorescence signal is prevalent in areas corresponding to the brain and lumbar spinal cord. Tissue sections from EAE mice also were confirmed by immunohistochemistry at 7 days after MSCs-IFNβ treatment. Photon emission detected by the Maestro in vivo imaging system arose from the presence of NIR labeled MSCs inside the tissues as demonstrated by the detection of hNA-positive elements (green) inside the brain and spinal cord (Figure 6(a)). This result demonstrates that MSCs-IFNβ
also have migratory properties toward the inflamed CNS and could cross the BBB. Inflammation, demyelination, and BBB breakdown are the most common descriptive events in MS. In our experiment, the permeability of BBB of different treated animals was detected by quantitative measurement for EB content at day 7 after treatment. PBS-treated EAE mice showed a significant increase in the content of EB in the brain and spinal cord when compared with the normal control mice ($P < 0.01$). This result is consistent with the previous reports [21, 22]. Enhanced BBB permeability accompanying with large numbers of lymphocytes infiltrating into CNS plays an important role in the development and progression of MS and EAE. However, MSCs-IFNβ-treated EAE mice showed a significant decrease in the content of EB in the spinal cord when compared with the MSCs-GFP-treated EAE mice ($P < 0.05$). The results showed that MSCs-IFNβ treatment could prevent further injury of BBB permeability (Figure 6(b)). Reduced BBB permeability may suggest decreased lymphocytes infiltration into CNS then consequently reduced CNS inflammation and demyelination, which was in coincidence with the results of our histological evaluation in MSCs-IFNβ-treated EAE mice.

4. Conclusions

Many studies have been conducted in an attempt to verify the safety and efficiency of various stem cell therapies. hBM-MSCs autografts were one of the first successes in stem cell therapies as there is minimal chance of immune rejection due to their immunomodulatory properties [23]. In addition, these MSC transplantations do not typically result in teratoma formation when tested in clinical trials and are relatively safe compared to ESCs (embryonic stem cells) and iPSCs (induced pluripotent stem cells) which readily form teratomas [24]. Recently, MSC-based therapies have also been evaluated for their safety and varying levels of effectiveness for treating various neurodegenerative disorders, including MS [25, 26]. However, many questions remain regarding the true efficacy and precise mechanism of action of stem cell-based therapeutic approaches in MS. Further clinical trials will need to be carried out to verify the therapeutic efficiency and safety of MSC-based therapies in humans. In conclusion, this study demonstrated that hBM-MSCs can be used as a new delivery vehicle for IFN-β therapy against EAE, and MSCs-IFNβ exhibit strong therapeutic effects by decreasing inflammatory cell influx, suppressing demyelination and immunomodulatory effects by promoting a shift from the Th1 to the Th2 cytokine balance, stabilizing the BBB and preventing the progression of disease in EAE mice. Further studies are needed to identify the detailed mechanisms of therapeutic effect by MSCs-IFNβ in vivo.

Conflict of Interests

The authors declare no conflict of interests.

Acknowledgments

This study was supported by a Grant of the Korea Health Technology R&D Project, Ministry of Health & Welfare, Republic of Korea (A092258 and AI10330). The authors thank Genexine Co., Ltd., for providing them with Ad-IFN-β.

References

[1] P. A. Calabresi, “Diagnosis and management of multiple sclerosis,” The American Family Physician, vol. 70, no. 10, pp. 1935–1944, 2004.
[2] W. Castro-Borrero, D. Graves, T. C. Frohman et al., “Current and emerging therapies in multiple sclerosis: a systematic review,” Therapeutic Advances in Neurological Disorders, vol. 5, no. 4, pp. 205–220, 2012.
[3] C. H. Polman and B. M. J. Uitdehaag, “New and emerging treatment options for multiple sclerosis,” The Lancet Neurology, vol. 2, no. 9, pp. 563–566, 2003.
[4] R. H. Swanborg, “Experimental autoimmune encephalomyelitis in rodents as a model for human demyelinating disease,” Clinical Immunology and Immunopathology, vol. 77, no. 1, pp. 4–13, 1995.
[5] M. F. Pittenger, A. M. Mackay, S. C. Beck et al., “Multilineage potential of adult human mesenchymal stem cells,” Science, vol. 284, no. 5411, pp. 143–147, 1999.
[6] M. Abumaree, M. Al Jumah, R. A. Pace, and B. Kalionis, “Immunosuppressive properties of mesenchymal stem cells,” Stem Cell Reviews and Reports, vol. 8, no. 2, pp. 375–392, 2012.
[7] J. Lim, C. Jeong, J. Jun et al., “Therapeutic effects of human umbilical cord blood-derived mesenchymal stem cells after intrathecal administration by lumbar puncture in a rat model of cerebral ischemia,” Stem Cell Research and Therapy, vol. 2, no. 5, article 38, 2011.
[8] K. Le Blanc, I. Rasmussen, B. Sundberg et al., “Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells,” The Lancet, vol. 363, no. 9419, pp. 1439–1441, 2004.
[9] L. Bai, D. P. Lennon, V. Eaton et al., “Human bone marrow-derived mesenchymal stem cells induce Th2-polarized immune response and promote endogenous repair in animal models of multiple sclerosis,” GLIA, vol. 57, no. 11, pp. 1192–1203, 2009.
[10] J. Zhang, Y. Li, J. Chen et al., “Human bone marrow stromal cell treatment improves neurological functional recovery in EAE mice,” Experimental Neurology, vol. 195, no. 1, pp. 16–26, 2005.
[11] F. Manfredonia, L. Pasquali, A. Dardano, A. Ludice, L. Murri, and F. Monzani, “Review of the clinical evidence for interferon β 1a (Rebif) in the treatment of multiple sclerosis,” Neuropsychiatric Disease and Treatment, vol. 4, no. 2, pp. 321–336, 2008.
[12] S. Dhib-Jalbut and S. Marks, “Interferon-β mechanisms of action in multiple sclerosis,” Neurology, vol. 74, supplement 1, pp. S17–S24, 2010.
[13] W. Pan, W. A. Banks, and A. J. Kastin, “Permeability of the blood-brain and blood-spinal cord barriers to interferons,” Journal of Neuroimmunology, vol. 76, no. 1-2, pp. 105–111, 1997.
[14] A. M. Kim, J. Y. Lim, S. I. Park et al., “Gene therapy using TRAIL-secreting human umbilical cord blood-derived mesenchymal stem cells against intracranial glioma,” Cancer Research, vol. 68, no. 23, pp. 9614–9623, 2008.
[15] D. Goldstein, K. M. Siaff, B. E. Storer et al., “Human biologic response modification by interferon in the absence of measurable serum concentrations: a comparative trial of subcutaneous
and intravenous interferon-β serine,” *Journal of the National Cancer Institute*, vol. 81, no. 14, pp. 1061–1068, 1989.

[16] E. U. Walther and R. Hohlfeld, “Multiple sclerosis: side effects of interferon beta therapy and their management,” *Neurology*, vol. 53, no. 8, pp. 1622–1627, 1999.

[17] J. H. Seo and S.-R. Cho, “Neurorestoration induced by mesenchymal stem cells: potential therapeutic mechanisms for clinical trials,” *Yonsei Medical Journal*, vol. 53, no. 6, pp. 1059–1067, 2012.

[18] G. D’Intino, M. Paradisi, M. Fernandez et al., “Cognitive deficit associated with cholinergic and nerve growth factor down-regulation in experimental allergic encephalomyelitis rats,” *Proceedings of the National Academy of Sciences of the United States of America*, vol. 102, no. 8, pp. 3070–3075, 2005.

[19] D. Azoulay, K. Mausner-Fainberg, N. Urshansky, E. Fahoum, and A. Karni, “Interferon-β therapy up-regulates BDNF secretion from PBMCs of MS patients through a CD40-dependent mechanism,” *Journal of Neuroimmunology*, vol. 211, no. 1-2, pp. 114–119, 2009.

[20] P. Villolslada, S. L. Hauser, I. Bartke et al., “Human nerve growth factor protects common marmosets against autoimmune encephalomyelitis by switching the balance of T helper cell type 1 and 2 cytokines within the central nervous system,” *Journal of Experimental Medicine*, vol. 191, no. 10, pp. 1799–1806, 2000.

[21] J. Kraus, K. Voigt, A. M. Schuller et al., “Interferon-β stabilizes barrier characteristics of the blood-brain barrier in four different species in vitro,” *Multiple Sclerosis*, vol. 14, no. 6, pp. 843–852, 2008.

[22] J. Kraus, A. K. Ling, S. Hamm, K. Voigt, P. Oschmann, and B. Engelhardt, “Interferon-β stabilizes barrier characteristics of brain endothelial cells in vitro,” *Annals of Neurology*, vol. 56, no. 2, pp. 192–205, 2004.

[23] A. J. Nauta and W. E. Fibbe, “Immunomodulatory properties of mesenchymal stromal cells,” *Blood*, vol. 110, no. 10, pp. 3499–3506, 2007.

[24] P. S. Knoepfler, “Deconstructing stem cell tumorigenicity: a roadmap to safe regenerative medicine,” *Stem Cells*, vol. 27, no. 5, pp. 1050–1056, 2009.

[25] P. Connick, M. Kolappan, C. Crawley et al., “Autologous mesenchymal stem cells for the treatment of secondary progressive multiple sclerosis: an open-label phase 2a proof-of-concept study,” *The Lancet Neurology*, vol. 11, no. 2, pp. 150–156, 2012.

[26] J. S. Lee, J. M. Hong, G. J. Moon et al., “A long-term follow-up study of intravenous autologous mesenchymal stem cell transplantation in patients with ischemic stroke,” *Stem Cells*, vol. 28, no. 6, pp. 1099–1106, 2010.